Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach.
Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520666.
PMID: 42030501
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer. Sci Transl Med. 2026 Apr 22; 18(846):eaec2358.
PMID: 42018670
Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer.
Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520834.
PMID: 41990285
Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression.
Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression. Breast Cancer (Dove Med Press). 2026; 18:569936.
PMID: 42006742
Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape.
Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520506.
PMID: 41962061
Disparities in Disease Presentation and Treatment Initiation for De Novo Metastatic Breast Cancer.
Disparities in Disease Presentation and Treatment Initiation for De Novo Metastatic Breast Cancer. JAMA Netw Open. 2026 Apr 01; 9(4):e268908.
PMID: 42024379
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy. J Natl Compr Canc Netw. 2026 Mar 31; 24(3.5).
PMID: 42061438
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. J Clin Oncol. 2026 May 10; 44(14):1283-1295.
PMID: 41805422
Triple negative breast cancer: what clinical progress have we seen in the last 5?years?
Triple negative breast cancer: what clinical progress have we seen in the last 5?years? Expert Opin Investig Drugs. 2026 Mar; 35(3):223-238.
PMID: 41653123
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial. Res Sq. 2026 Feb 11.
PMID: 41727611